Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib

Jeffrey A. Jones; Peter Hillmen; Steven Coutre; Constantine Tam; Richard R. Furman; Paul M. Barr; Stephen J. Schuster; Thomas J. Kipps; Ian W. Flinn; Ulrich Jaeger; Jan A. Burger; Mei Cheng; Joi Ninomoto; Danelle F. James; John C. Byrd; Susan M. O'Brien

doi:10.1111/bjh.14660

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib

Jeffrey A. Jones, Peter Hillmen, Steven Coutre, Constantine Tam, Richard R. Furman, Paul M. Barr, Stephen J. Schuster, Thomas J. Kipps, Ian W. Flinn, Ulrich Jaeger, Jan A. Burger, Mei Cheng, Joi Ninomoto, Danelle F. James, John C. Byrd, Susan M. O'Brien

Research output: Contribution to journal › Article › Research › peer-review

65 Citations (Scopus)

Abstract

Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications.

Original language	English
Pages (from-to)	286-291
Number of pages	6
Journal	British Journal of Haematology
Volume	178
Issue number	2
DOIs	https://doi.org/10.1111/bjh.14660
Publication status	Published - Jul 2017
Externally published	Yes

Keywords

anticoagulation
bleeding
chronic lymphocytic leukaemia
haemorrhage
ibrutinib

Access to Document

10.1111/bjh.14660Licence: CC BY-NC-ND

Cite this

Jones, J. A., Hillmen, P., Coutre, S., Tam, C., Furman, R. R., Barr, P. M., Schuster, S. J., Kipps, T. J., Flinn, I. W., Jaeger, U., Burger, J. A., Cheng, M., Ninomoto, J., James, D. F., Byrd, J. C., & O'Brien, S. M. (2017). Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. British Journal of Haematology, 178(2), 286-291. https://doi.org/10.1111/bjh.14660

@article{08917e5dca154ad6acf25904c7c348d2,

title = "Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib",

abstract = "Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications.",

keywords = "anticoagulation, bleeding, chronic lymphocytic leukaemia, haemorrhage, ibrutinib",

author = "Jones, {Jeffrey A.} and Peter Hillmen and Steven Coutre and Constantine Tam and Furman, {Richard R.} and Barr, {Paul M.} and Schuster, {Stephen J.} and Kipps, {Thomas J.} and Flinn, {Ian W.} and Ulrich Jaeger and Burger, {Jan A.} and Mei Cheng and Joi Ninomoto and James, {Danelle F.} and Byrd, {John C.} and O'Brien, {Susan M.}",

note = "Funding Information: We thank the patients who participated in these studies, their supportive family members, and the investigators and clinical research staff from the study centers. This study was sponsored by Pharmacyclics LLC, an AbbVie Company. Medical writing assistance in the preparation of this manuscript was provided by Maoko Naganuma, MSc, CMPP, and was funded by Pharmacyclics LLC, an AbbVie Company. Publisher Copyright: {\textcopyright} 2017 John Wiley & Sons Ltd",

year = "2017",

month = jul,

doi = "10.1111/bjh.14660",

language = "English",

volume = "178",

pages = "286--291",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "2",

}

Jones, JA, Hillmen, P, Coutre, S, Tam, C, Furman, RR, Barr, PM, Schuster, SJ, Kipps, TJ, Flinn, IW, Jaeger, U, Burger, JA, Cheng, M, Ninomoto, J, James, DF, Byrd, JC & O'Brien, SM 2017, 'Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib', British Journal of Haematology, vol. 178, no. 2, pp. 286-291. https://doi.org/10.1111/bjh.14660

TY - JOUR

T1 - Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib

AU - Jones, Jeffrey A.

AU - Hillmen, Peter

AU - Coutre, Steven

AU - Tam, Constantine

AU - Furman, Richard R.

AU - Barr, Paul M.

AU - Schuster, Stephen J.

AU - Kipps, Thomas J.

AU - Flinn, Ian W.

AU - Jaeger, Ulrich

AU - Burger, Jan A.

AU - Cheng, Mei

AU - Ninomoto, Joi

AU - James, Danelle F.

AU - Byrd, John C.

AU - O'Brien, Susan M.

N1 - Funding Information: We thank the patients who participated in these studies, their supportive family members, and the investigators and clinical research staff from the study centers. This study was sponsored by Pharmacyclics LLC, an AbbVie Company. Medical writing assistance in the preparation of this manuscript was provided by Maoko Naganuma, MSc, CMPP, and was funded by Pharmacyclics LLC, an AbbVie Company. Publisher Copyright: © 2017 John Wiley & Sons Ltd

PY - 2017/7

Y1 - 2017/7

N2 - Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications.

AB - Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications.

KW - anticoagulation

KW - bleeding

KW - chronic lymphocytic leukaemia

KW - haemorrhage

KW - ibrutinib

UR - http://www.scopus.com/inward/record.url?scp=85017446605&partnerID=8YFLogxK

U2 - 10.1111/bjh.14660

DO - 10.1111/bjh.14660

M3 - Article

C2 - 28397242

AN - SCOPUS:85017446605

SN - 0007-1048

VL - 178

SP - 286

EP - 291

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib

Abstract

Keywords

Access to Document

Other files and links

Cite this